post Thursday September 19, 2013
In a development that sends a positive signal about the developing protection and importance of intellectual property in China, MMR Global Inc. announced the recognition of an important patent for its line of cancer fighting drugs.
MMR Global Inc. is a leading biotech and pharmaceutical company that has a handful drugs designed to treat and attack various forms of cancer and non-Hodgkin’s Lymphoma. MMR Global Inc. is seeking to expand their patent portfolio and the overall scope of their biotech assets.
An additional fact about this recent recognition of patent is MMR Global Inc. participated in the so called Patent Prosecution Highway Program. This program enabled the issuance of patents to MMR Global Inc. for their anti-CD20 monoclonal antibodies that are protected in the United States. The Patent Prosecution Highway Program made the process of receiving protection for the antibodies in China much more efficient and affordable while ensuring a more effective protection and support of MMR Global’s patents.
While MMR Global Inc. has obtained protection of their anti-CD20 monoclonal antibodies in China, MMR Global still has outstanding patent requests in other developing countries. The countries that MMR Global is seeking to have protection of their IP include Brazil, Hong Kong, Europe, India, Japan, Korea and Canada. The anti-CD20 monoclonal antibodies are a key portion of the company’s expansion strategy in the global market for drugs treating related types of cancer.
Source: AG-IP News
Image source: FreeDigitalPhotos.net
